The FDA has issued an advisory warning to physicians and patients about potential health risks from topical anesthetic lidocaine used to reduce the discomfort of breast compression during mammography.
The FDA has issued an advisory warning to physicians and patients about potential health risks from topical anesthetic lidocaine used to reduce the discomfort of breast compression during mammography.
Dr. Colleen K. Lambertz and colleagues at St. Luke's Mountain States Tumor Institute in Boise, ID, discussed the potential value of nonprescription lidocaine gel spread before mammography in the September 2008 issue of Radiology (248[3]:765-771). Lambertz reported that lidocaine produced a few minor side effects, but the FDA noted in January that the study was not large enough to evaluate the potential for serious reactions. The deaths of two women who used topical anesthetics prior to laser hair removal led the FDA to issue in early 2007 an advisory on potentially lifethreatening side effects of skin products containing numbing ingredients and guidelines for safer use.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
Surveillance Breast MRI Associated with Lower Risks of Advanced Second Breast Cancers
January 8th 2025After propensity score matching in a study of over 3,000 women with a personal history of breast cancer, researchers found that surveillance breast MRI facilitated a 59 percent lower risk in advanced presentations of second breast cancers.